Frequently bought together

Brand : CLIMEN

CLIMEN 2/1/MG FC TAB 21/TAB

23.7

Sku : I-015640
Key features
Climen Coated Tablet 2.1 mg is a prescription medicine containing cyproterone acetate 2 mg and estradiol 1 mg. It works as a cyclic combined hormone replacement therapy, with estradiol helping to replace estrogen and cyproterone acetate providing progestogenic and anti-androgenic activity. It is used for the treatment of menopausal symptoms and for hormone replacement therapy in women who require cyclic estrogen-progestogen support. It is supplied as coated tablets in a pack of 21 tablets.
- Brand: CLIMEN
- Active Ingredient: CYPROTERONE ACETATE 2mg, ESTRADIOL 1mg
- Strength: 2,1mg
- Dosage Form: Coated tablet
- Pack Size: 21 Tablets
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Hormonal
- Pharmacological Group: Sex Hormones
- Drug Class: Systemic combined estrogen-progestogen HRT; estradiol (estrogen) + cyproterone acetate (progestogen with anti-androgenic activity); ATC G03CA53.
- Manufacturer: BAYER WEIMAR GmbH UND CO. KG
- Country of Origin: Germany
- SFDA Registration No.: 3009245993
- Shelf Life: 36 months
- Storage: store below 25°c
- Hormone Type: Combined
- Method: Oral

Frequently bought together

Description

Specification

Dosage & Administration

Maximum Dose

1 tablet orally once daily for 21 days per cycle (do not exceed 1 tablet/day).

Drug Interactions

Interaction Severity

Clinically significant interactions: enzyme inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St John’s wort) may reduce hormone exposure/efficacy; strong CYP3A4 inhibitors (e.g., azole antifungals, some macrolides) may increase exposure; monitor with anticoagulants (e.g., warfarin) and ciclosporin due to potential effect changes.

Special Populations

Breastfeeding

Contraindicated

Liver Impairment

Contraindicated in severe or active hepatic disease; in mild-moderate impairment use only with caution and close monitoring, and discontinue if liver function deteriorates.

Pharmacology

Mechanism of Action

Estradiol replaces endogenous estrogen to relieve menopausal symptoms; cyproterone acetate provides progestogenic activity to oppose estrogen-driven endometrial proliferation (reducing hyperplasia risk) and has anti-androgen receptor activity; together they provide cyclic HRT.

Half-Life

Cyproterone acetate: terminal half-life about 1.6-1.8 days (≈38-44 hours); Estradiol (oral): short effective half-life on the order of hours (commonly cited ~12-20 hours depending on matrix/measured analyte).

Metabolism

Estradiol is extensively metabolized in the liver (and gut) to estrone/estriol and conjugates; cyproterone acetate is hepatically metabolized (largely via CYP3A4) to hydroxylated metabolites including 15β-hydroxy-cyproterone acetate.

Excretion

Cyproterone acetate: metabolites eliminated via both feces and urine (predominantly biliary/fecal with a substantial renal fraction); Estradiol metabolites: mainly excreted in urine as sulfate/glucuronide conjugates (with some biliary/fecal elimination).